Enable JavaScript to visit this website.

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve.

Click here to learn how we are responding.

Skip to main content
Back to top

IMPORTANT SAFETY INFORMATION AND INDICATION

CHANTIX is contraindicated in patients with a history of serious hypersensitivity or skin reactions to CHANTIX.

Postmarketing reports of serious or clinically significant neuropsychiatric adverse events have been reported in patients treated with CHANTIX. These included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Observe patients attempting to quit smoking with CHANTIX for the occurrence of such symptoms and instruct them to discontinue CHANTIX and contact a healthcare provider immediately if they experience such adverse events.

During clinical trials and the postmarketing experience, there have been reports of seizures in patients treated with CHANTIX, with or without a history of seizures. CHANTIX should be used cautiously in patients with a history of seizures or other factors that can lower the seizure threshold. Instruct patients to discontinue CHANTIX, and contact a healthcare provider immediately if they experience a seizure while on treatment.

There have been postmarketing reports of patients experiencing increased intoxicating effects of alcohol while taking CHANTIX, including unusual and sometimes aggressive behavior directed to oneself or to others and often accompanied by amnesia. Advise patients to reduce the amount of alcohol they consume while taking CHANTIX until they know whether CHANTIX affects their tolerance for alcohol.

Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke.

Cases of somnambulism have been reported in patients taking CHANTIX. Some cases described harmful behavior to self, others, or property. Instruct patients to discontinue CHANTIX and notify their healthcare provider if they experience somnambulism.

Patients should be informed that there have been reports of serious skin reactions, such as Stevens Johnson Syndrome and Erythema Multiforme and of angioedema, with swelling of the face, mouth, and neck that can lead to life-threatening respiratory compromise. Patients should be instructed to discontinue CHANTIX and immediately seek medical care if they experience these symptoms or at the first sign of rash with mucosal lesions or any other signs of hypersensitivity.

The most common adverse reactions include nausea (30%), abnormal dreams, constipation, flatulence, and vomiting. Patients should be informed that they may experience vivid, unusual, or strange dreams during treatment with CHANTIX. Patients should be advised to use caution driving or operating machinery or engaging in other potentially hazardous activities until they know how CHANTIX may affect them.

Safety and efficacy of CHANTIX in combination with other smoking cessation drug therapies have not been studied. Dosage adjustment with CHANTIX is recommended in patients with severe renal impairment or in patients undergoing hemodialysis.

Smoking cessation, with or without treatment with CHANTIX, may alter the pharmacokinetics or pharmacodynamics of some drugs, such as theophylline, warfarin, and insulin. Dosage adjustment for these drugs may be necessary.

INDICATION

CHANTIX is indicated as an aid to smoking cessation treatment in adults.

Please see full Prescribing Information and Medication Guide.

Are your patients in need of prescription assistance?

Pfizer RxPathways® connects eligible patients to assistance programs that offer insurance support, co-pay assistance, and medicines for free or at a savings.

Learn more by visiting
www.PfizerRxPathways.com or
calling 1-844-989-PATH (7284)

Terms and conditions apply.
 
 
Back to top
Pfizer Home
  • CHANTIX Home

Clinical Information

  • Flexibility in Setting a Quit Date
  • Efficacy
  • Safety
  • Dosing and Administration

Support & Services

  • Clinical Resources
  • Cost and Coverage
  • Patient Support
  • Study Designs
  • Welcome Kit and Savings Card

Main menu

  • Pfizer Products
  • Support & Services

User menu

  • Sign In
  • Register

This site is intended for U.S. health care professionals.

  • Prescribing Information including boxed warning
  • Indication
  • Important Safety Information
  • Medication Guide

CHANTIX Indication

Clinical Information

  • Flexibility in Setting a Quit Date
  • Efficacy
  • Safety
  • Dosing and Administration

Support & Services

  • Clinical Resources
  • Cost and Coverage
  • Patient Support
  • Study Designs
  • Welcome Kit and Savings Card

See CHANTIX quit approach details

View EAGLES efficacy results

Learn more about CHANTIX savings

Learn how to prescribe CHANTIX

Watch the CHANTIX MOA video now

Reference: 1. CHANTIX [package insert]. New York, NY: Pfizer Inc; 2018.

IMPORTANT SAFETY INFORMATION AND INDICATION

CHANTIX is contraindicated in patients with a history of serious hypersensitivity or skin reactions to CHANTIX.

Postmarketing reports of serious or clinically significant neuropsychiatric adverse events have been reported in patients treated with CHANTIX. These included changes in mood (including depression and mania), psychosis, hallucinations, paranoia, delusions, homicidal ideation, aggression, hostility, agitation, anxiety, and panic, as well as suicidal ideation, suicide attempt, and completed suicide. Observe patients attempting to quit smoking with CHANTIX for the occurrence of such symptoms and instruct them to discontinue CHANTIX and contact a healthcare provider immediately if they experience such adverse events.

During clinical trials and the postmarketing experience, there have been reports of seizures in patients treated with CHANTIX, with or without a history of seizures. CHANTIX should be used cautiously in patients with a history of seizures or other factors that can lower the seizure threshold. Instruct patients to discontinue CHANTIX, and contact a healthcare provider immediately if they experience a seizure while on treatment.

There have been postmarketing reports of patients experiencing increased intoxicating effects of alcohol while taking CHANTIX, including unusual and sometimes aggressive behavior directed to oneself or to others and often accompanied by amnesia. Advise patients to reduce the amount of alcohol they consume while taking CHANTIX until they know whether CHANTIX affects their tolerance for alcohol.

Patients with underlying cardiovascular (CV) disease may be at increased risk of CV events; however, these concerns must be balanced with the health benefits of smoking cessation. Instruct patients to notify their healthcare providers of new or worsening CV symptoms and to seek immediate medical attention if they experience signs and symptoms of myocardial infarction (MI) or stroke.

Cases of somnambulism have been reported in patients taking CHANTIX. Some cases described harmful behavior to self, others, or property. Instruct patients to discontinue CHANTIX and notify their healthcare provider if they experience somnambulism.

Patients should be informed that there have been reports of serious skin reactions, such as Stevens Johnson Syndrome and Erythema Multiforme and of angioedema, with swelling of the face, mouth, and neck that can lead to life-threatening respiratory compromise. Patients should be instructed to discontinue CHANTIX and immediately seek medical care if they experience these symptoms or at the first sign of rash with mucosal lesions or any other signs of hypersensitivity.

The most common adverse reactions include nausea (30%), abnormal dreams, constipation, flatulence, and vomiting. Patients should be informed that they may experience vivid, unusual, or strange dreams during treatment with CHANTIX. Patients should be advised to use caution driving or operating machinery or engaging in other potentially hazardous activities until they know how CHANTIX may affect them.

Safety and efficacy of CHANTIX in combination with other smoking cessation drug therapies have not been studied. Dosage adjustment with CHANTIX is recommended in patients with severe renal impairment or in patients undergoing hemodialysis.

Smoking cessation, with or without treatment with CHANTIX, may alter the pharmacokinetics or pharmacodynamics of some drugs, such as theophylline, warfarin, and insulin. Dosage adjustment for these drugs may be necessary.

INDICATION

CHANTIX is indicated as an aid to smoking cessation treatment in adults.

Please see full Prescribing Information and Medication Guide.

Are your patients in need of prescription assistance?

Pfizer RxPathways® connects eligible patients to assistance programs that offer insurance support, co-pay assistance, and medicines for free or at a savings.

Learn more by visiting
www.PfizerRxPathways.com or
calling 1-844-989-PATH (7284)

Terms and conditions apply.
 
 
Back to top

To report an adverse event, please call 1-800-438-1985

Footer logo

Footer links

  • Report Adverse Events
  • Terms of Use
  • Cookies & Privacy Policy
  • Contact
  • Pfizer.com
  • Patient Assistance

Copyright footer block

Pfizer for Professionals 1-800-505-4426

The product information provided in this site is intended only for healthcare professionals in the United States.
The products discussed may have different product labeling in other countries.

© 2021 Pfizer Inc. All Rights Reserved.

PP-CHM-USA-2586